Anthropic’s Claude agents outperformed human researchers and produced “alien science,” raising new questions about AI ...
Meta's new hyperagent framework breaks the AI "maintenance wall," allowing systems to autonomously rewrite their own logic ...
Infosecurity outlines key recommendations for CISOs and security teams to implement safeguards for AI-assisted coding ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...
Researchers discovered an appetite-suppressing molecule in python blood. If one day turned into a medication, it might lack ...
In just a few short months, Marathon has minted a highly quotable line: “Escape will make me God.” It’s also, according to ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results